Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of Chinese traditional medicine for treating viral myocarditis and preparation method

A technology for viral myocarditis and composition, applied in the directions of drug delivery, antiviral agents, pharmaceutical formulations, etc., can solve the problems of no disease research, no development of new traditional Chinese medicines with unique curative effects, no drugs with very precise curative effects, etc., to achieve protection Cardiomyocyte function, increase myocardial nutrient blood flow, and improve microcirculation

Inactive Publication Date: 2008-07-16
惠汝太
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in terms of traditional Chinese medicine treatment in my country, there has been no medicine with very definite curative effect. Most doctors add and subtract medicine flavors on the basis of empirical prescriptions, combined with Western medicine treatment measures
Neither in-depth research on diseases nor development of new traditional Chinese medicines with unique curative effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of Chinese traditional medicine for treating viral myocarditis and preparation method
  • Combination of Chinese traditional medicine for treating viral myocarditis and preparation method
  • Combination of Chinese traditional medicine for treating viral myocarditis and preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Embodiment 1, medicine preparation

[0048] 1. Materials:

[0049] (1) Source and dosage of raw materials:

[0050] 1. Astragalus This product is the dried root of the leguminous plant Astragalus mongolica or Astragalus membranaceus. Excavated in spring and autumn, remove fibrous roots and roots, and dry in the sun. Main production: Shanxi, Inner Mongolia, Gansu, Heilongjiang.

[0051] 2. Rhodiola This product is the dry root and rhizome of Rhodiola grandiflora or Rhodiola grandiflora of Crassulaceae. Excavated in autumn, removed the rough bark, and sun-dried. Main production: Tibet, Gansu, Xinjiang, Jilin and other places.

[0052] 3. Sophora flavescens This product is the dried root of the leguminous plant Sophora flavescens. Excavated in spring and autumn, removed root heads and small branches, washed, dried, or sliced ​​while fresh, dried. Main production: Shanxi, Inner Mongolia, Gansu, Heilongjiang. Produced in most parts of the country.

[0053] The consu...

Embodiment 2

[0089] Embodiment 2, in vitro pharmacodynamics test 1——CPE inhibition experiment at the cardiomyocyte level

[0090] 1. Test materials:

[0091] 1. Test drug: the traditional Chinese medicine composition described in Example 1 of the present invention, the production batch number is: 030904;

[0092] 2. Experimental animals: SD suckling mice, which are second-class animals (certificate number SXK-11-00-0006), were purchased from the Institute of Zoology, Chinese Academy of Medical Sciences;

[0093] 3. Coxsackie virus CVB 3 : The strain number is Nancy strain, provided by the virus room of Wuhan Union Medical College Hospital.

[0094] 2. Test method:

[0095] (1) CVB 3 Virus virulence titration method (TCID 50 , 50% tissue culture infectious dose):

[0096] 1. Experimental steps:

[0097] Culture Vero cells in a 96-well plate; the virus was serially diluted 10-fold with serum-free medium, respectively 10 -1 ~10 -8 Dilution, then seeded in 96-well plate (the wells are...

Embodiment 3

[0132] Embodiment 3, in vitro pharmacodynamics test 2 - virus reproduction inhibition test

[0133] 1. Test materials:

[0134] Vero cells, Coxsackie virus CVB 3 And test drug: with embodiment 2.

[0135] 2. Test method:

[0136] 1. Inoculate Vero cells on a 24-well plate, and then add drugs and viruses in groups. The experimental design is shown in Table 13:

[0137] Table 13-well plates were inoculated with Vero cells and added drugs and viruses in groups

[0138]

[0139] 2. Harvest grouped cells according to different harvest time, and titrate CVB with virus titration method 3 virulence.

[0140] 3. Test results:

[0141] Harvest grouped cells according to different harvest time, and titrate CVB with virus titration method 3 Virulence, then TCID calculated by the Reed-Muench method 50 , the result is as image 3 shown.

[0142] In the development of antiviral drugs, if the drug can reduce the titer of the virus by more than 1 logarithmic value, it is considered...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A Chinese medicine for treating viral myocarditis is prepared from astragalus root, rhodiola root and flavescent sophora root. Its preparing process is also disclosed.

Description

technical field [0001] The invention relates to a traditional Chinese medicine composition for treating viral myocarditis and a preparation method thereof, and belongs to the field of traditional Chinese medicine modernization. Background technique [0002] Viral myocarditis (VMC) is a common and frequently-occurring disease of the cardiovascular system, and it is also one of the main causes of dilated cardiomyopathy, heart failure and sudden death. At present, whether in developed countries or in developing countries, the incidence of myocarditis has increased significantly compared with 10 years ago, mainly due to the increased incidence of viral myocarditis in infectious myocarditis. According to the World Health Organization (WHO) global virus surveillance research report: in newborns and children's sudden death cases, 20% are caused by viral myocarditis; the incidence rate of viral myocarditis in newborns and children is 360 / 10 10,000, the mortality rate is 8%; the inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/489A61K36/481A61K36/41A61K9/00A61P31/12
Inventor 惠汝太宋晓东陈敬洲甄一松邹玉宝马平祝立新
Owner 惠汝太
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com